Otsuka Pharmaceutical Co. Ltd.
www.otsuka.co.jp/en/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Otsuka Pharmaceutical Co. Ltd.
Taiho’s Lytgobi Faces Heavy Competition, But Sets Efficacy Bar For Now
The FGFR inhibitor beats prior entrants on efficacy in cholangiocarcinoma, although Relay presented data at ESMO for its investigational RLY-4008 showing especially high efficacy and tolerability.
Deal Watch: Roche, PhoreMost Enter Into Multi-Target Collaboration
Plus deals with Synaffix/Emergence, Helsinn/Juniper and Sanyou/Shanghai KangaBio, while Takeda/Finch and Dong-A/Beactica ended prior collaborations.
Pharma, Non-Profits Ally To Advance TB Drug Combinations
The Project to Accelerate New Treatments for Tuberculosis (PAN-TB) is pulling together philanthropic, non-profit and private sector participants to collaboratively run Phase II trials for five drugs from Janssen, Otsuka, the TB Alliance and the Bill & Melinda Gates Medical Research Institute.
Lundbeck Ready To File Alzheimer’s Agitation Treatment, A Potential First
Brexpiprazole could be approved as soon as 2023, and Lundbeck has pledged to support its uptake with investment in its salesforce and direct-to-consumer advertising.
Company Information
- Industry
- Medical Devices
-
Pharmaceuticals
- Nutraceuticals
- OTC, Consumer
-
In Vitro Diagnostics
- Chemistry, Immunoassay